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ABSTRACT
Introduction: Scarring on visible areas such as
the face is associated with negative
psychological impact. Many patients with acne
have clinically relevant scarring for which they
seek treatment, implying that there is an impact
on their lives. Currently there are no validated
tools to assess the burden of atrophic acne
scarring from the patient’s perspective or to
assess treatment benefit.
Methods: Two patient-reported outcome
measures, the self-assessment of clinical
acne-related scars (SCARS) and the facial acne
scar quality of life (FASQoL) tools, both specific
to facial atrophic acne scarring, were developed
according to Food and Drug Administration
guidance methodology. Patient interviews were
conducted first to elicit patient-important
concepts about scarring, then to validate
patients’ understanding of wording in the
On behalf of the Global Alliance to Improve Outcomes
in Acne.
Electronic supplementary material The online
version of this article (doi:10.1007/s13555-016-0098-5)
contains supplementary material, which is available to
authorized users.
A. Layton
Department of Dermatology, Harrogate District
Hospital, Harrogate, UK
B. Dre´no
Department of Dermatology, Hotel Dieu, Nantes,
France
A. Y. Finlay
Department of Dermatology, Cardiff University
School of Medicine, Cardiff, UK
D. Thiboutot
Department of Dermatology, Hershey University,
Hershey, PA, USA
S. Kang
Department of Dermatology, Johns Hopkins School
of Medicine, Baltimore, MA, USA
V. T. Lozada
Department of Dermatology, Juarez Hospital,
Mexico City, Mexico
V. Bourde`s (&)  L. Petit
Galderma R & D, Sophia Antipolis, France
e-mail: valerie.bourdes@galderma.com
V. Bettoli
Department of Dermatology, University of Ferrara,
Ferrara, Italy
J. Tan
Department of Dermatology, University of Western
Ontario, Windsor, Canada
Dermatol Ther (Heidelb) (2016) 6:219–233
DOI 10.1007/s13555-016-0098-5
tools. These tools focus on symptoms (SCARS)
and psychological and social well-being
(FASQoL) and were designed to be suitable for
self-completion and to be rapidly completed
(2–5 min) within a clinical research setting.
Results: Concept elicitation interviews were
conducted with 30 subjects and cognitive
interviews with 20 subjects. With acne
scarring, important concepts for patients
included size, surface area affected, counts,
and depth. The SCARS and FASQoL tools were
shown to address relevant concepts that were
easily understood by patients.
Conclusion: Two patient-reported measures,
SCARS and FASQoL, have been developed to
help clinicians assess the severity and impact of
acne scars. Responsivity of these instruments to
treatment will require further evaluation.
Funding: Galderma R&D, Sophia Antipolis,
France.
Keywords: Acne; Atrophic scar;
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INTRODUCTION
Scarring is a frequent occurrence among
patients with acne. Most patients have some
degree of scarring and approximately 40% of all
acne patients have clinically relevant scars [1,
2]. There is a significant correlation between
acne severity and likelihood of acne scarring [3],
but scars can occur with acne of any severity,
including mild [1, 2]. In an international study
of over 6000 patients, scarring was present in
26.7% of subjects with mild acne, 51.3% of
those with moderate acne, and 76.7% of those
with severe acne [3].
In 2010, the Global Alliance to Improve
Outcomes in Acne group created an initiative to
improve understanding of acne scarring. Acne
scarring can involve either loss (atrophic) or
excessive accumulation (hypertrophic) of tissue
with differing pathogenesis and clinical
management [4]. Atrophic acne scarring is
more common in clinical practice; accordingly
the initial focus was on atrophic acne scarring.
Up to that time, few studies of acne scarring had
been conducted and most focused on
management. There were relatively few
standardized and validated tools for clinical
assessment of acne-related scarring; even expert
dermatologists may disagree about how to
describe acne scars in a consistent way [2,
5–9]. No validated patient assessment
instruments specific for acne scarring were
found in the literature and only sparse studies
of impact of atrophic acne scarring on quality of
life (QoL) [10]. Patients with acne scarring
(particularly on the face) seek treatment for
these scars, implying that there is an impact on
their lives [11]. Further, psychosocial morbidity
may be linked with acne scarring [4, 12, 13].
However, no QoL tools specifically address the
impact of atrophic acne scarring and limited
data suggest that acne QoL measures are not
sensitive for acne scarring [14]. Ilgen et al. [14]
tested the Acne Quality of Life Scale (AQOLS)
and the Dermatology Life Quality Index (DLQI)
in 108 patients and found no difference
between those with or without scarring. It
should be noted that neither the AQOLS nor
the DLQI was designed for the purpose of
assessing acne scars; thus, it would not be
surprising if they were not sensitive or specific
in evaluating the effects of scarring. A more
recent acne-specific QoL scale [Acne Symptom
and Impact Scale (ASIS)] included an item about
‘‘scars/scabs/dark marks’’, but this tool addressed
acne as a global disease and was not specific for
atrophic acne scars [15]. To address specifically
acne scarring evaluation, we developed two
220 Dermatol Ther (Heidelb) (2016) 6:219–233
instruments to help patients describe the
severity of their atrophic acne scars
[Self-assessment of Clinical Acne-Related Scars
(SCARS) questionnaire] and to assess the impact
of atrophic acne scars on QoL [Facial Acne Scar
Quality of Life (FASQoL) questionnaire] [16].
The aim of this study was to develop these
scar tools based on patients’ input according
to Food and Drug Administration (FDA)
guidance on patient-reported outcomes
(PROs). Measurement properties of the two
instruments will be tested in a further step.
METHODS
The protocol for the creation of the patient
assessment tools followed the classical steps for
developing and qualitatively testing a PRO
instrument in accordance with the US FDA
PRO Guidance [16]. Since the FDA PRO
Guidance notes that a fundamental
consideration in the development and use of a
PRO instrument is whether an instrument’s
concepts are clearly defined and appropriate to
the population of interest, these steps include:
(1) elicitation of the concepts of interest
regarding appearance, symptoms, impacts,
bothersomeness [through concept elicitation
(CE) interviews with specific questionnaires];
(2) generation of items, selection and
implementation of the most relevant signs
(items); and (3) testing of patient
understanding of the draft instrument through
cognitive interviews (CIs). Details of the
methodology used are presented in Fig. 1.
CE interviews were designed to probe aspects
of import to patients and items explored
included symptoms, impact, description of
appearance and severity of atrophic acne scars,
and bothersomeness. The number of CE
interviews was determined based on saturation
achievement—the point when no more unique
concepts arose. In an independent sample of
subjects, understanding of concepts and item
wording was tested through CIs. All the
interviews were conducted in the USA.
Ethical Conduct of the Interviews
All interviews were performed in accordance
with the ethical principles of the Declaration of
Helsinki and consistent with Good Clinical
Practice and applicable regulatory
requirements. Medical and all other
information collected during the study was
kept confidential. Copernicus Group, Durham,
NC, USA, served as the Independent Review
Board (IRB).
Recruitment
After obtaining IRB approval, patients were
recruited through a recruitment agency that
accepted centralized IRB approval based on the
finalized study inclusion and exclusion criteria
(same for both sets of interviews). The
recruitment agency was provided with study
objectives prior to the start of recruitment;
dermatologists from an existing database were
contacted to identify patients with atrophic
acne scars. Adult candidates (18 years old and
above) completed a Subject Information and
Consent Form including an Authorization to
Use and Disclose Personal Health Information
for Research Form. Adolescent patients
(12–17 year olds) and their parents/legal
guardians completed an Adolescent Assent
Form and an accompanying Parental
Permission and Health Insurance Portability
and Accountability Act (HIPAA) Form. After
written informed consent and authorization
was obtained, the clinicians confirmed patient
eligibility for the study in person.
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Inclusion/Exclusion Criteria
All subjects had atrophic acne scars; active acne
could be present, and recruitment was designed
to include equal numbers of subjects with mild,
moderate, and severe acne. Subjects also had to
be willing and able to provide informed consent
or assent (for adolescent subjects), to speak US
English, and to participate in study procedures.
Subjects were excluded if they had hypertrophic
and/or keloidal scars, a skin condition in the
area of acne scars that would interfere with
study procedures (e.g., plaque psoriasis, tattoo,
birthmark, facial hair), or a significant medical
condition that would confound study results or
interfere significantly with a subject’s
involvement in the study. Targeted patients
had a range of active acne severity (no active
acne with only scars to grade 4 severity with
scars) [2] and were grouped in two groups of
skin types: light to medium (Fitzpatrick skin
type I–IV) and dark skin (Fitzpatrick skin type V
and VI) [3].
For the CE interviews, 30 subjects were
recruited and interviewed with a range of acne
lesion and acne scar severities. Severity was
classified using Investigator Global Assessment
(IGA) and the Scar Global Assessment (SGA). An
additional group of 20 subjects with atrophic
acne scars was recruited to participate in
individual face-to-face CIs.
Conduct of Interviews
A subgroup of experts from the Global Alliance
to Improve Outcomes in Acne constituted a
Fig. 1 Methodology for developing patient-reported outcomes tool
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Board of Experts for the development of these
tools, providing definitions of atrophic scars for
a user manual guide for the recruitment process.
Patients with scars excluded from the
assessment according to the guide were not
evaluated. Atrophic acne scars were defined as
the permanent loss of tissue following acne
lesions (not induced by manipulation or
excoriation).
All interviews were conducted by trained
personnel (National Institutes of Health
Participant Protection training). Prior to the
interviews, mock interviews were conducted to
review the interview guide and ensure good
interviewing practices. Interviews lasted up to
60 min and interviewers followed a
semi-structured Interview Guide. Subjects were
asked open-ended questions, followed by more
targeted, probing questions if needed. The
open-ended approach ensured that subjects
were not unduly biased and elicited the
language subjects use to describe what they
believe to be the symptoms and impacts of their
acne scars. In addition to the open-ended
questions, subjects were asked to rank the
severity of scars in photos to further engage
them and elicit more information on symptoms,
impacts and description of appearance and
severity of atrophic acne scars. Subjects were
asked to focus responses on atrophic acne scars
and to exclude pigmentary changes, scars from
other etiologies (e.g., trauma, varicella), and
hypertrophic/keloidal scars.
Data Handling
Interviews were recorded and transcribed, and
coding for key concepts was performed, then
analyzed. The content of SCARS and FASQoL
tools was selected based upon results from the
CE interviews. Special attention was given to
the importance and relevance of concepts based
on the frequency with which they were
reported by interviewed patients.
Cognitive Interviews
The objectives of the CIs were to evaluate each
item from the instruments for adequacy of the
following properties: relevance of all of the
items (and domains, if any) covered by the
instruments; comprehensiveness (content
validity) of the items; comprehensibility,
applicability, and acceptability of the items;
and instruments or items appear to measure
what they should measure. Furthermore, CIs
were conducted to evaluate clarity and ease of
comprehension on first reading.
The CIs were conducted in two phases.
During the first phase, subjects were asked to
complete the draft instruments and provide
feedback. They were asked to think aloud about
the process they used to arrive at each answer
and to identify words, terms, or concepts that
were difficult to interpret or understand. They
were also asked if they would make changes to
improve the usefulness of the tools. Following
this first phase, the instruments were revised
based on patient feedback as well as expert
input. The revised instruments were cognitively
debriefed in a second phase of CIs. Similar to
the first phase of CIs, patients were asked to
complete the PRO instruments using a think
aloud method. Patient feedback on
item/concept relevance, comprehensiveness
and interpretability was also collected. The
revised instrument was re-submitted to the IRB
for approval before use in the second phase of
CIs. The interviews lasted approximately 1 h
and were audio-recorded (with subjects’ prior
consent) and transcribed verbatim and
anonymized. The results from these interviews
were coded and compared in a fashion similar
to that used with the CE interviews.
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Statistical Analysis
Analysis of qualitative data collected during
interviews involved constant comparison and
traditional content tabulations. Qualitative data
were analyzed using ATLAS.ti version 7.0
(Atlas.ti GmbH, Berlin, Germany), a software
package designed specifically for the analysis of
qualitative data. Researchers trained in
qualitative methods and coding developed a
coding scheme that was applied to all
transcripts. A saturation grid was developed to
compare the amount of new information
elicited and analyzed periodically during the
interview process to determine that saturation
had been reached. The goal of the saturation
grid was to compare the amount of new or
‘‘novel’’ information that was observed.
Responses from the interviews were grouped
by domain, concept, and patient. Further
analysis compared the number of responses
elicited from the first 25% of patients to the
next 25% of patients, then from the first 50% of
patients to the next 25% of patients, and finally
from the first 75% of patients to the last 25% of
patients. This allowed researchers to determine
if and when new concepts were elicited as data
collection neared completion and, ultimately,
to determine if saturation was met within the
number of interviews conducted. The
saturation results determined whether or not
additional interviews should be conducted.
RESULTS
Patient Populations
Group 1: Concept Elicitation
A total of 30 subjects participated in the CE
interviews (15 adults and 15 adolescents). The
mean age of the adults was 31.0 years (range
20.3–50.6 years) and the mean age of
adolescents was 16.0 years (range
13.8–17.8 years). Most adults (73.3%) were
female; 40.0% of the adolescents were female.
Approximately half of subjects had mild acne
(adults 56.7%, adolescents 50.0%), one-third
had moderate acne (adults 23.3%, adolescents
33.3%) and a small group had severe acne
(adults 20.0%, adolescents 16.7%). Fitzpatrick
I–III types were regrouped in light to medium
skin class, and Fitzpatrick IV–VI types into dark
skin class. Table 1 presents information about
the duration of acne and acne scars as well as
scar severity for the group.
Group 2: Cognitive Interviews
Twenty CIs were conducted in two phases to
allow adjustment and improvement of the
SCARS and FASQoL instruments after the first
phase. Subjects included eight adolescents
(mean age 16.6 years) and 12 adults (mean age
35.6 years). Among these, 11 (55%) were
female; 11 (55%) had a light to medium skin
type while 9 (45%) had a dark skin type; 2
patients (10%) had scars only, 6 (30%) had mild
active acne, 7 (35%) had moderate active acne,
and 5 (25%) had severe acne.
Concept Elicitation
Among all concepts (n = 60) expressed by
patients across the symptom and impact
domains, the vast majority (n = 58) were
reported prior to the final quartile of
interviews. The two concepts that were
reported for the first time in the final quartile
[sensitivity (as a symptom of acne scars) and
talking too much (as a coping mechanism to
distract from acne scars)] were mentioned by
only one patient each (3.3%). Therefore, these
concepts are considered idiosyncratic to a small
minority of patients. As such, saturation was
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considered to be achieved for appearance,
severity, symptom, and impact concepts. The
sample size of 30 patients was sufficient to
conclude that no new meaningful concepts
would emerge even if additional interviews
were conducted.
Appearance, Severity, and Symptoms
Associated with Acne Scars
During CE interviews, patients discussed the
physical attributes and severity of their acne
scars (Fig. 2). These were organized under the
domains appearance, severity, and symptoms.
Among the appearance factors, frequently
reported concepts included color (n = 24,
80.0%), size (n = 24, 80.0%), and location/area
(n = 22, 73.3%). Somewhat frequently reported
concepts included texture (n = 13, 43.3%),
number (n = 13, 43.3%), shape (n = 12,
40.0%), and depth (n = 11, 36.6%). Among the
severity factors (i.e., factors patients considered
when describing scar severity), frequently
reported concepts were color (n = 21, 70.0%),
number (n = 20, 66.6%), size (n = 19, 63.3%),
and location/area (n = 17, 56.6%); somewhat
frequently reported concepts were depth
(n = 12, 40.0%) and texture (n = 11, 36.6%).
Most Bothersome Appearance Factors
In the discussion of appearance factors
associated with acne scars, patients
highlighted those factors that were most
bothersome: color (n = 7, 23.3%), depth
(n = 2, 6.6%), number (n = 2, 6.6%), and size
(n = 1, 3.3%). Patients explained that these
appearance factors were bothersome because
they felt that their scars were noticeable (n = 7,
23.3%), numerous (n = 2, 6.6%), dark (n = 2,
6.6%), created an uneven skin tone (n = 1,
3.3%), and would not go away (n = 1, 3.3%).
Table 1 Scar and acne severity in concept elicitation
interview population
Group 1 (n5 30)
Scar severity
Mild 36.7% (11)
Moderate 36.7% (11)
Severe 26.7% (8)
Acne severity
Scars only 16.7% (5)
Mild acne ? scars 13.3% (4)
Moderate acne ? scars 46.7% (14)
Severe acne ? scars 23.3% (7)
Group 2 (n5 20)
Scar severity
Mild 50.0% (10)
Moderate 30.0% (6)
Severe 20.0% (4)
Acne severity
Scars only 10.0% (2)
Mild acne ? scars 30.0% (6)
Moderate acne ? scars 35.0% (7)
Severe acne ? scars 25.0% (5)
Values are presented as % (n)
Fig. 2 Factors patients identiﬁed important in determin-
ing acne scar severity
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Impact on Patients’ Life
During CE interviews, patients explained the
effect that acne scars had on their lives (Fig. 3).
Among the acne scar impact concepts, two were
frequently reported: feeling less attractive
(n = 25, 83.3%) and feeling self-conscious
(n = 20, 66.6%). Other impacts included
confidence (n = 10, 33.3%), annoyed (n = 10,
33.3%), worried about scars not going away
(n = 9, 30.0%), depressed feeling (n = 8, 26.6%),
upset by negative comments from others
(n = 10, 33.3%), avoiding or changing social
activities (n = 7, 23.3%), dating (n = 7, 23.3%),
bothered having to spend time putting make-up
on (n = 7, 23.3%), and impacts to work/school
life (n = 8, 26.6%). Although two coping
mechanisms and moderating factors (having
to cover scars with make-up and washing one’s
face) were somewhat frequently reported, these
do not pertain directly to either scar severity or
impacts, and therefore were not included in the
development of the PRO. On the other hand,
the impact on patients’ relationships
(specifically dating), though infrequently
reported (n = 4, 13.3%), was recommended for
inclusion to broadly understand the impact of
acne scars on patients’ relationships with
friends, family, and significant others.
Most Bothersome Life Impacts
Most commonly, patients identified impacts to
their appearance/attractiveness (n = 5, 16.6%),
confidence (n = 4, 13.3%), social activities
(n = 4, 13.3%), and the inconvenience of using
make-up (n = 4, 13.3%) as the most bothersome.
Three patients (10.0%) each reported worrying
about the permanence of acne scars and impacts
to work/school life as the most bothersome,
while another two patients (6.6%) each reported
worrying about what others think, people
staring, romantic relationships, and emotional
impacts generally. One patient (3.3%) each
reported that comments from others, feeling
embarrassed, and feeling self-conscious were the
most bothersome impacts.
Operationalization of the Concepts
and Instrument Development
The results of the CE interviews and initial
drafts of items were presented to the clinical
experts from the Global Alliance. Content for
both instruments was selected based upon
results from the CE interviews. In particular,
special attention was given to the importance
and relevance of concepts based on the
frequency of report by interviewed patients.
Item Wording and Structure
The specific wording for the instruments was
based on the actual words and phrases that
patients used to talk about their scars during the
CE interviews and on standard language
conventions used for instrument development
(e.g., avoiding medical jargon and use of vague
terms). The definition of atrophic acne scars
included in both PRO instruments was
informed by the words patients used as well as
expert input. The terms that were most used by
both adult and adolescent patients to describe
Fig. 3 Concepts most bothersome to acne scar subjects
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atrophic acne scars were ‘‘indents’’ and ‘‘holes.’’
Other terms suggested by the experts for
consideration such as dips, pits, pinholes,
sunken areas, and stretches were mentioned
infrequently by patients (n\3). Therefore, the
definition included in the instructions of both
PROs was ‘‘atrophic acne scars are indents or
holes in the skin from previous acne spots.’’
Recall Period
To use the SCARS tool, patients are instructed to
look in the mirror and assess appearance
concepts at the present moment. This method
was used to minimize measurement bias
introduced by memory problems. For the
FASQoL, the recall of recent states (no more
than 1 week) was preferable and also served to
minimize measurement bias introduced by
memory problems while still providing the
patient a long enough timeframe to
experience the impacts being assessed.
Response Options
All of the items in the instruments include
response options based on a five-point
Likert-type scale. Both instruments were
designed to be a self-report in the clinical
research setting. In the current development
program, subjects were asked to complete the
questionnaire using a paper-and-pen format.
Cognitive Interview Results
Phase I
The following revisions were made to the
instructions to help patients understand the
differences between active acne and acne scars
and reflect patient language.
• The language for active acne lesions and
atrophic acne scars was simplified;
• To help patients understand active acne and
acne scars, ‘‘active acne’’ was revised to ‘‘zits,
breakouts, pimples, whiteheads, or
blackheads,’’ and ‘‘acne scars’’ was revised to
‘‘indents or holes’’ in the items.
• All references to post active acne lesions were
removed;
• ‘‘Facial jewelry/piercings’’ was added at the
beginning of the VAS instructions based on
expert feedback;
• The item wording was revised from ‘‘uneven’’
to ‘‘rough’’ based on patient feedback during
CEs and to help patients understand the
intended interpretation.
Phase II
No new items were added to the SCARS initially
developed, as patient suggestions were
inconsistent with one another or were not
relevant to the measurement goals. All
patients (n = 12, 100.0%) demonstrated no
difficulty interpreting the instructions as
intended. No revisions were made, but
training is recommended prior to the use of
the instrument in clinical trials to help patients
understand the differences between active acne
and atrophic acne scars. Patients appeared to
have difficulty interpreting the concept of
roughness for item 5 and the item was deleted.
Item 6 (noticeability) was reworded to ensure
that patients consider the visibility of their acne
scars to themselves and not to others. The order
of items 2 (amount) and 3 (size) was reversed to
help patients with the understanding of
coverage and amount of acne scars.
Overall, subjects provided positive feedback
on the SCARS and FASQoL questionnaires. The
majority of concepts were relevant and
understood by subjects; items were worded so
that subjects could provide meaningful
responses. SCARS is a 5-item questionnaire
(Table 2). The FASQoL includes 10 items
assessing atrophic acne scar-related impacts
(Table 3).
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Table 2 SCARS patient-reported outcome tool
Assessment of Acne Scar Appearance and Severity: Part 1 
Please remove all make-up and facial jewelry/piercings, and e back any loose hair covering your face before answering this 
quesonnaire.
Please begin by answering the quesons below.  These quesons will help you understand the diﬀerence between acve acne and 
atrophic acne scars.
The following queson asks you about atrophic acne scars only.  Please do not consider acve acne (zits, breakouts, pimples, 
whiteheads, or blackheads), scabs, or ﬂat red or dark marks.
Assessment of Acne Scar Appearance and Severity: Part 2
The following quesons ask you about atrophic acne scars only.  Remember, atrophic acne scars are indents or holes in the skin from 
previous acve acne.  Please do not consider acve acne (zits, breakouts, pimples, whiteheads, or blackheads), scabs, or ﬂat red or dark 
marks. 
Please read each queson, then look in the mirror and think about the indents or holes on your whole face, and then answer the 
queson.  Please mark an “X” in the box ( ) that best describes how the indents or holes on your face look RIGHT NOW.
There are no right or wrong answers to these quesons.  If you want to change your answer, please cross out your original answer and 
mark an “X” in the correct box.
Please choose only one response.
1. When looking at your face in the mirror right now, how much of your face looks covered by indents or holes?
a) Acve acne includes zits, breakouts, pimples, whiteheads, and blackheads.
When looking at your face in the mirror right now, do you see zits, breakouts, pimples, whiteheads, or blackheads?
Yes / No (please circle one)
please rate the severity of the zits, breakouts, pimples, whiteheads, or blackheads on your face by pung a vercal line in If yes, 
the place that best describes your acne.
No acve acne Very severe acve acne
0 10
b) Atrophic acne scars are indents or holes in the skin from previous acve acne (not from injury, scratching or picking).
When looking at your face in the mirror right now, do you see indents or holes in the skin from previous acve acne?
Yes / No (please circle one)
If you answered “No” for this queson, you have completed this quesonnaire.  Thank you for your me. 
please rate the severity of the indents or holes on your face by pung a vercal line in the place that best describes yourIf yes, 
scars.
No indents
or holes
Very severe
indents or holes
0 10
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DISCUSSION
Skin disease can have profound and long-lasting
impact on those affected [17]. While many with
atrophic acne scars seek treatment, little is
known about the impact of this condition. It
is generally assumed that acne scars have a
negative impact on QoL [18]. The Global
Alliance scar working group is working to
develop a variety of acne-scarring specific tools
for both subjects and clinicians, with a goal of
providing a more standardized and focused
understanding of acne scars’ severity. This
report describes the development of a
patient-reported severity assessment (SCARS)
and a QoL assessment tool (FASQoL), both
developed in accordance with the FDA PRO
Guidance. These tools are intended to provide
information about changes that occur during
acne treatment (including changes in scar
severity and possible prevention of new scars),
and we feel this justifies the inclusion of
patients with both active acne and scars.
During the development process, several
considerations emerged. First, differentiation
of active acne, post-inflammatory erythema
and hyperpigmentation from scars is difficult
for the lay public. We found it is essential to
incorporate lay language, with the simplest
terminology possible. Important concepts for
subjects in determining acne scar severity
included number, size, location/area, depth,
Table 2 continued
Almost none
of my face
A lile
of my face
Some
of my face
A lot
of my face
Almost all
of my face
2. When looking at your face in the mirror right now, how small or large do the individual indents or holes look?
Very small Small Moderate Large Very large
3. When looking at your face in the mirror right now, how many indents or holes do you see?
Very few
indents or holes
A few
indents or holes
Some
indents or holes
Quite a lot of
indents or holes
Many
indents or holes
4. When looking at your face in the mirror right now, how deep do the individual indents or holes look?
Not at all
deep
A lile
deep
Moderately
deep
Very
deep
Extremely
deep
5. When looking at your face in the mirror right now, how visible are the indents or holes to you?
Not at all
visible
A lile
visible
Moderately
visible
Very
visible
Extremely
visible
© Galderma 2013 All Rights Reserved.
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Table 3 Facial acne scar quality of life (FASQoL) questionnaire
Acne Scar Quality of Life Quesonnaire
The following quesons ask you about how the atrophic acne scars on your face impact your daily life.  Atrophic acne scars are indents 
or holes in the skin from previous acve acne (not from injury, scratching or picking).
When answering these quesons, please do not consider any of the following:
• Zits, breakouts, pimples, whiteheads, or blackheads on the face;
• Acne scabs (dry, rough protecve crusts that form over zits or pimples before indents or holes develop); or
• Flat red or dark marks.
Please mark an “X” in the box ( ) that best describes the impact that the indents or holes on your face had on you over the PAST 7 
DAYS.  
There are no right or wrong answers to these quesons.  If you want to change your answer, please cross out your original answer and 
mark an “X” in the correct box. Please choose only one response.
1. Over the past 7 days, have you felt self-conscious when you were with people because of the indents or holes on your face? 
Not at all
self-conscious
A lile
self-conscious
Somewhat
self-conscious
Very
self-conscious
Extremely
self-conscious
2. Over the past 7 days, have you felt less aracve because of the indents or holes on your face?
I did not feel less 
aracve
A lile
less aracve
Somewhat
less aracve
Much
less aracve
Extremely
less aracve
3. Over the past 7 days, have you felt annoyed because of the indents or holes on your face?
Not at all
annoyed
A lile
annoyed
Somewhat
annoyed
Very
annoyed
Extremely
annoyed
4. Over the past 7 days, have you felt worried that the indents or holes on your face won’t go away?
Not at all
worried
A lile
worried
Somewhat
worried
Very
worried
Extremely
worried
5. Over the past 7 days, have you felt sad because of the indents or holes on your face?
Not at all sad A lile sad Somewhat sad Very sad Extremely sad
6. Over the past 7 days, have you felt upset by negave comments from others because of the indents or holes on your face?
Not at all upset A lile upset Somewhat upset Very upset Extremely upset
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and texture (skin evenness). Patients also
indicated color was important. However, color
is confounded when active acne or post-acne
lesions are present [post-inflammatory
hyperpigmentation (PIH)], therefore an item
on color was not included.
SCARS is a 5-item instrument with one
hypothesized domain that asks subjects to rate
the severity of acne scars as seen in a mirror. The
tool starts with two visual analog scales to
remind the patient to separate active acne
lesions from acne scars. Use of a short
photographic training manual for patients
could help to optimize the sensitivity of this
tool. FASQoL is a 10-item instrument with three
domains assessing the impact of scars on
emotions, social functioning and work/school
on 5-point rating scales with a recall period of
the past 7 days. The content of the two tools has
been validated from patient’s perspective and is
ready for psychometric validation.
We believe the development of scar-specific
tools is important since there is some evidence
showing that existing tools lack sensitivity and
specificity to assess the impact of scars. In
general, more generic health-related
instruments are less sensitive than
disease-specific measures [19]. To our
knowledge, no prior patient-reported atrophic
acne scar-specific measure has been developed.
Brown et al. [19] reported the development of a
patient-reported scar assessment tool
[patient-reported impact of scars measure
(PRISM)], but it includes scars of differing
etiologies and assesses both symptoms and
QoL impact. It is the first tool we know of
based on patient input that measures the global
impact of scars from the patient’s viewpoint. It
Table 3 continued
7. Over the past 7 days, have the indents or holes on your face made you avoid going out with friends or family?
Not at all A lile Somewhat Very much Extremely
8. Over the past 7 days, have you felt bothered by having to hide the indents or holes on your face?
Not at all
bothered
A lile
bothered
Somewhat
bothered
Very
bothered
Extremely
bothered
9. Over the past 7 days, have the indents or holes on your face aﬀected your relaonships with others (for example, friends, 
family, romanc relaonships/partner)?
Not at all A lile Somewhat Very Extremely
10. Over the past 7 days, have the indents or holes on your face aﬀected your parcipaon at work or school?
Not at all A lile Somewhat Very Extremely
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would be interesting to compare PRISM with
our tools to find areas of agreement and
disagreement. Similarly, the tool developed by
Alexis et al. [15] was designed primarily to assess
active acne, but it incorporates some questions
about scars/scabs/marks. We feel this could be
useful to provide an overall assessment of the
patient’s experience of acne, but may not be
applicable as an outcome measure for
management of the group of patients with
scars, but no active acne.
The study had some limitations; first,
interviews were conducted only in the USA.
Adaptation of the two PRO instruments for use
in other patient populations will be needed,
following the conduct of translatability testing
and additional CIs. Translatability testing and
additional patient interviews would ensure
content validity across other languages and
cultures. In addition, there is a need to assess
the measurement properties of the two PRO
instruments to provide evidence for the
reliability and construct validity of the
instruments. Finally, responsiveness to
treatment should be assessed.
CONCLUSIONS
As treatments emerge for acne scarring, tools
that address the patient’s perspective are
becoming increasingly important. We have
created tools to inform clinicians about the
patients’ perspectives that can be used in both
routine practice and clinical studies to help
clinicians manage patients with acne scars. We
followed the rigorous recommendations given
by FDA guidance for developing two PRO tools
(SCARS and FASQoL) and found that the
concepts included are relevant to the
condition and that the tools created are easily
understood, simple to complete, and contain
information relevant to daily activities. To
assess sensitivity to treatment benefit, SCARS
and FASQoL should be evaluated in a clinical
trial with a treatment known to improve and/or
prevent scars.
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